Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-VM: Targeted Therapies for Vascular Malformations
NCT05983159Phase 2Recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib, mirdametinib in vascular malformation, sponsored by Murdoch Children's Research Institute. Started Sep 2024; status: recruiting.
02
Drugs
alpelisibmirdametinib
03
Conditions
vascular malformation
Beyond the preview
Go deeper on NCT05983159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983159.